Health & Fitness
Health and Fitness
Health and Fitness
Fri, November 11, 2011
Thu, November 10, 2011
New Data Confirms Early Implantation of Impella 2.5 Prior to PCI Improves Survival in Shock Patients
DANVERS, Mass. & SAN FRANCISCO--([ BUSINESS WIRE ])--[ Abiomed Inc ]. (NASDAQ: ABMD), a leading provider of [ breakthrough heart support technologies ], today announced new results from a multicenter retrospective study demonstrating that early initiation of support with Impella? 2.5 prior to revascularization improves survival in emergent patients as compared to those receiving Impella 2.5 support after percutaneous coronary intervention (PCI). Specifically, the analysis demonstrated that shock patients that received Impella before revascularization had a higher survival rate (65% vs. 39%, p=0.007 respectively, N=119).
"A hemodynamic support device is recommended for patients with cardiogenic shock after STEMI who do not quickly stabilize with pharmacological therapy (384,424?427). (Level of Evidence: B)."
The results of the study were presented today by William O?Neill, M.D. of the University of Miami, at the annual 2011 Transcatheter Cardiovascular Therapeutics (TCT) meeting and included 119 patients receiving emergent PCI with Impella at 32 U.S. centers.
The data from this analysis supports the recently released new ACCF/AHA/SCAI guidelines which included Impella as a Class I recommendation for cardiogenic shock after STEMI.
5.2.3 Cardiogenic Shock Class I: Recommendation: ?A hemodynamic support device is recommended for patients with cardiogenic shock after STEMI who do not quickly stabilize with pharmacological therapy (384,424?427). (Level of Evidence: B).?
This is an ongoing registry that continues to analyze this data and collect data for the Impella patient population. The slides from this presentation will be made available on [ www.TCTMD.com ] on Friday, November 11, 2011.
ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Our products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping of the heart. For additional information please visit: [ www.abiomed.com ].
FORWARD-LOOKING STATEMENTS
This Release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K and most recently filed Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.
